GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Asset Turnover

Enzo Biochem (Enzo Biochem) Asset Turnover : 0.08 (As of Jan. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Enzo Biochem's Revenue for the three months ended in Jan. 2024 was $8.55 Mil. Enzo Biochem's Total Assets for the quarter that ended in Jan. 2024 was $102.69 Mil. Therefore, Enzo Biochem's Asset Turnover for the quarter that ended in Jan. 2024 was 0.08.

Asset Turnover is linked to ROE % through Du Pont Formula. Enzo Biochem's annualized ROE % for the quarter that ended in Jan. 2024 was -16.88%. It is also linked to ROA % through Du Pont Formula. Enzo Biochem's annualized ROA % for the quarter that ended in Jan. 2024 was -11.92%.


Enzo Biochem Asset Turnover Historical Data

The historical data trend for Enzo Biochem's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Asset Turnover Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.69 1.04 0.35 0.32

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.22 -0.20 0.07 0.08

Competitive Comparison of Enzo Biochem's Asset Turnover

For the Diagnostics & Research subindustry, Enzo Biochem's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Asset Turnover falls into.



Enzo Biochem Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Enzo Biochem's Asset Turnover for the fiscal year that ended in Jul. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jul. 2023 )/( (Total Assets (A: Jul. 2022 )+Total Assets (A: Jul. 2023 ))/ count )
=31.061/( (75.611+121.88)/ 2 )
=31.061/98.7455
=0.31

Enzo Biochem's Asset Turnover for the quarter that ended in Jan. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jan. 2024 )/( (Total Assets (Q: Oct. 2023 )+Total Assets (Q: Jan. 2024 ))/ count )
=8.553/( (106.308+99.077)/ 2 )
=8.553/102.6925
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Enzo Biochem  (NYSE:ENZ) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Enzo Biochem's annulized ROE % for the quarter that ended in Jan. 2024 is

ROE %**(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-12.244/72.525
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.244 / 34.212)*(34.212 / 102.6925)*(102.6925/ 72.525)
=Net Margin %*Asset Turnover*Equity Multiplier
=-35.79 %*0.3331*1.416
=ROA %*Equity Multiplier
=-11.92 %*1.416
=-16.88 %

Note: The Net Income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Enzo Biochem's annulized ROA % for the quarter that ended in Jan. 2024 is

ROA %(Q: Jan. 2024 )
=Net Income/Total Assets
=-12.244/102.6925
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-12.244 / 34.212)*(34.212 / 102.6925)
=Net Margin %*Asset Turnover
=-35.79 %*0.3331
=-11.92 %

Note: The Net Income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Enzo Biochem Asset Turnover Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203